Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness and Expected Launch of Novel Therapies

  • ID: 4720215
  • Report
  • Region: Asia, Asia Pacific
  • 113 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • Amorepacific
  • Astellas
  • Cyclosporine
  • Genentech
  • Kang Stem Biotech
  • LEO Pharma
  • MORE

Atopic Dermatitis (AD), also called Atopic Eczema, is a chronic, pruritic, inflammatory skin disease associated with cutaneous hyper reactivity to environmental stimulants, with a wide range of severity. Patients typically experience periods of remission that are marked by acute inflammatory relapses known as ‘flares’. It is one of the most common skin diseases, affecting approximately 20% of children and 1-3% of adults in most countries. Atopic Dermatitis (AD) is slightly more common in males aged 6-7 and in females aged 13-14.

Atopic Dermatitis (AD) is a complex disease with a wide spectrum of symptoms affecting 15-20% of children and 1-3% of adults globally. Recent studies showed that its incidence has increased two to three fold in industrialized countries and its prevalence is increasing rapidly in low-income countries. The rising prevalence population, together with improving health awareness among the public and healthcare professionals, special healthcare programs, increasing health-insurance coverage, healthcare access and affordability will increase diagnosis and the treatment-receiving population, driving demand and contributing to market growth.

Southeast Asian Atopic Dermatitis (AD) market (South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia) is forecast to grow at a compound annual growth rate (CAGR) of 10.5% from 2017 to 2024.

The increase in uptake of recently approved and emerging targeted therapeutics, along with the continued uptake of existing branded therapies, will also propel market growth. Dupixent has the potential to be a game-changing therapy, as it is a first-in-class IL-drug and the first biologic approved for the treatment of Atopic Dermatitis (AD). In addition, Dupixent’s expected launch in Singapore and Taiwan will be the most important event in the Atopic Dermatitis (AD) market space in the near-term. The continued uptake of this novel targeted therapy will contribute to the increasing ACoT and in turn drive the market in South Korea, Singapore and Taiwan.

In recent years, targeted therapies have become a focus for Atopic Dermatitis (AD) treatment research. Biologics, small molecule and other therapies targeting specific immune pathways for Atopic Dermatitis (AD) are currently being studied in various phases along the drug development pipeline. The late-stage pipeline contains promising therapies that have the potential to achieve approval and launch over the forecast period.

On the other hand, novel topical therapies are still needed in the Atopic Dermatitis (AD) disease space, as current topical options are limited to corticosteroids and calcineurin inhibitors, which are associated with side effects, a long treatment duration, and low compliance. The launch of new pipeline therapies with better clinical profiles will significantly increase the treatment options for Atopic Dermatitis (AD) patients and improve care levels. Due to the positive impact expected to be made by therapies over the forecast period, the Atopic Dermatitis (AD) market is anticipated to undergo expansion in South East Asia.

Scope

  • The Southeast Asia AD market will be valued at $848.6m in 2024, growing from $423.2m in2017, at a compound annual growth rate of 10.5%.
  • What are the key factors driving the Southeast Asia AD treatment market?
  • What classes of drugs dominate the market?
  • How will the market respond to recent approval?
  • How will novel IL-4Ra inhibitor therapy Dupixent, which holds first-to-market advantage, contribute to growth?
  • The AD pipeline contains a range of molecule types and molecular targets, including those that are well established in AD and novel target therapies.
  • Which classes of novel drugs are most prominent in the pipeline?
  • What are the common targets and mechanisms of action of pipeline therapies?
  • Late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
  • How have the late-stage therapies performed in clinical trials?
  • What are the commercial prospects for the most promising late-stage products?
  • How will the approval of tralokinumab, furestem-AD, baricitinib, PAC-14028 and PF-04965842, affect the competitive landscape?
  • Various drivers and barriers will influence the market over the forecast period.
  • Which factors are most likely to drive the market in these countries?
  • What licensing and co-development deals have occurred within this therapy area since 2007?

Reasons to buy
This report will enable you to:

  • Understand the current clinical and commercial landscape of AD by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.
  • Visualize the composition of the AD market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
  • Consider market opportunities and potential risks by examining trends in AD clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict AD market growth in the eight assessed Southeast Asian markets, with epidemiological and annual cost of therapy forecasts across South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia, as well as the individual contributions of promising late-stage molecules to market growth.
  • Discover trends in licensing and co-development deals concerning AD products and identify the major strategic consolidations that have shaped the commercial landscape.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amorepacific
  • Astellas
  • Cyclosporine
  • Genentech
  • Kang Stem Biotech
  • LEO Pharma
  • MORE

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.4.1 Etiology
2.4.2 Pathophysiology
2.5 Diagnosis
2.5.1 Hanifin and Rajka Diagnostic Criteria
2.5.2 UK Working Party’s Diagnostic Criteria
2.5.3 Biomarkers
2.6 Classification and Disease Stages
2.7 Prognosis
2.8 Treatment Options and Guidelines
2.8.1 Emollients
2.8.2 Topical corticosteroids
2.8.3 Topical calcineurin inhibitors
2.8.4 Antimicrobials
2.8.5 Systemic immunosuppressive therapy
2.8.6 Biologics
2.8.7 Other treatments
2.8.8 Wet wrap therapy
2.9 Treatment guidelines

3 Marketed Products
3.1 Overview
3.1.1 Dupixent (dupilumab) - Regeneron and Sanofi
3.1.2 Protopic (tacrolimus) - Astellas
3.1.3 Elidel (Pimecrolimus) - Novartis
3.1.4 Cyclosporine
3.1.5 Xolair (omalizumab) - Novartis and Genentech (Off-Label Therapy)
3.1.6 Eucrisa (crisaborole) - Pfizer
3.1.7 Other Therapeutic Drug Classes Used in Atopic Dermatitis
3.2 Comparative Efficacy and Safety of Marketed Products

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 Tralokinumab - LEO Pharma
4.4.2 Furestem-AD - Kang Stem Biotech
4.4.3 Baricitinib - Eli Lilly and Incyte Corporation
4.4.4 PAC-14028- Amorepacific
4.4.5 PF-04965842 - Pfizer
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitiveness Framework

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecule Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Trial by Molecule Type and Stage of Development
5.2.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
5.2.3 Patient Enrollment per Product by Molecule Type and Stage of Development
5.2.4 Patient Enrollment per Product by Molecular Target and Stage of Development
5.3 Clinical Trial Duration
5.3.1 Clinical Trial Duration by Molecule Type
5.3.2 Clinical Trial Duration by Molecular Target
5.4 Competitive Clinical Trials Metrics Analysis

6 Multi-scenario Forecast
6.1 Geographical Market
6.2 Southeast Asian Markets
6.3 South Korea
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 Singapore
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Taiwan
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 Malaysia
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Philippines
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size
6.8 Thailand
6.8.1 Treatment Usage Patterns
6.8.2 Annual Cost of Therapy
6.8.3 Market Size
6.9 Vietnam
6.9.1 Treatment Usage Patterns
6.9.2 Annual Cost of Therapy
6.9.3 Market Size
6.10 Indonesia
6.10.1 Treatment Usage Patterns
6.10.2 Annual Cost of Therapy
6.10.3 Market Size

7 Drivers and Barriers
7.1 Drivers
7.1.1 Increasing awareness and diversified healthcare reform to boost market growth
7.1.2 Promising pipeline products that target unmet needs for AD
7.1.3 Restoring skin barrier function remains a key goal of disease management, meaning a continued need for moisturizers and topical agents
7.2 Barriers
7.2.1 First to second line of therapy is dominated by cheap, genericized topical drugs which create significant obstacles for novel drugs hoping to penetrate the market
7.2.2 Pediatric sufferers are the largest patient group and pose a high bar in terms of safety for new products
7.2.3 The complexity of the multiple etiologies that lead to AD means that treatment outcomes with existing drugs are not universal across all patient groups

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by region, value, year, stage of development, molecule type and molecular target
8.2.2 Key Co-development Deals

9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Phase I
9.1.4 Phase II
9.1.5 Phase III
9.2 Summary of Multi-Scenario Market Forecasts to 2024
9.2.1 Southeast Asia
9.2.2 South Korea
9.2.3 Singapore
9.2.4 Taiwan
9.2.5 Malaysia
9.2.6 Philippines
9.2.7 Thailand
9.2.8 Vietnam
9.2.9 Indonesia
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis
9.6 Contact Us
9.7 Disclaimer

List of Tables
Table 1: Hanifin and Rajka Diagnostic Criteria
Table 2: UK Working Party’s Diagnostic Criteria
Table 3: Classification of Atopic Dermatitis Based on Severity, Symptoms and Impact on Quality of Life
Table 4: Atopic Dermatitis Therapeutics, Southeast Asia, Summary of Other Therapeutic Classes for Atopic Dermatitis
Table 5: Atopic Dermatitis Therapeutics Market, Global, Licensing Deals with Disclosed Deal Value, 2007-2018
Table 6: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Discovery, 2018
Table 7: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Preclinical, 2018
Table 8: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Phase I, 2018
Table 9: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Phase II, 2018
Table 10: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Phase III, 2018
Table 11: Atopic Dermatitis Therapeutics Market, Southeast Asia, Market Forecast, 2017-2024
Table 12: Atopic Dermatitis Therapeutics Market, South Korea, Market Forecast, 2017-2024
Table 13: Atopic Dermatitis Therapeutics Market, Singapore, Market Forecast, 2017-2024
Table 14: Atopic Dermatitis Therapeutics Market, Taiwan, Market Forecast, 2017-2024
Table 15: Atopic Dermatitis Therapeutics Market, Malaysia, Market Forecast, 2017-2024
Table 16: Atopic Dermatitis Therapeutics Market, Philippines, Market Forecast, 2017-2024
Table 17: Atopic Dermatitis Therapeutics Market, Thailand, Market Forecast, 2017-2024
Table 18: Atopic Dermatitis Therapeutics Market, Vietnam, Market Forecast, 2017-2024
Table 19: Atopic Dermatitis Therapeutics Market, Indonesia, Market Forecast, 2017-2024

List of Figures
Figure 1: Atopic Dermatitis Therapeutics, South Korea, Age-Specific Prevalence (%), 2012
Figure 2: Prevalence of Atopic Dermatitis Associated Symptoms
Figure 3: Treatment Algorithm for Atopic Dermatitis Based on Severity
Figure 4: Atopic Dermatitis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of Atopic Dermatitis
Figure 5: Atopic Dermatitis Therapeutics Market, Global, Overview of Pipeline Products, 2018
Figure 6: Atopic Dermatitis Therapeutics Market, Global, Pipeline by Molecular Target, 2018
Figure 7: Atopic Dermatitis Therapeutics Market, Southeast Asia, Tralokinumab, Market Forecast ($m), 2021-2024
Figure 8: Atopic Dermatitis Therapeutics Market, Southeast Asia, Furestem-AD, Market Forecast ($m), 2021-2024
Figure 9: Atopic Dermatitis Therapeutics Market, Southeast Asia, Baricitinib, Market Forecast ($m), 2020-2024
Figure 10: Atopic Dermatitis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products
Figure 11: Atopic Dermatitis Therapeutics Market, Competitor Matrix for AD Marketed and Pipeline Products
Figure 12: Atopic Dermatitis Therapeutics Market, Global, Average Clinical Trial Failure Rate (%), 2007-2018
Figure 13: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Failure Rates by Molecule Type (%), 2007-2018
Figure 14: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007-2018
Figure 15: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2007-2018
Figure 16: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2007-2018
Figure 17: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007-2018
Figure 18: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target (participants), 2007-2018
Figure 19: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2007-2018
Figure 20: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2007-2018
Figure 21: Atopic Dermatitis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 22: Atopic Dermatitis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 23: Atopic Dermatitis Therapeutics Market, Southeast Asia, Treatment Usage Pattern (million), 2017-2024
Figure 24: Atopic Dermatitis Therapeutics Market, Southeast Asia, Market Size ($m), 2017-2024
Figure 25: Atopic Dermatitis Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2017-2024
Figure 26: Atopic Dermatitis Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017-2024
Figure 27: Atopic Dermatitis Therapeutics Market, South Korea, Market Size ($m), 2017-2024
Figure 28: Atopic Dermatitis Therapeutics Market, Singapore, Treatment Usage Patterns (million), 2017-2024
Figure 29: Atopic Dermatitis Therapeutics Market, Singapore, Annual Cost of Therapy ($), 2017-2024
Figure 30: Atopic Dermatitis Therapeutics Market, Singapore, Market Size ($m), 2017-2024
Figure 31: Atopic Dermatitis Therapeutics Market, Taiwan, Treatment Usage Patterns (million), 2017-2024
Figure 32: Atopic Dermatitis Therapeutics Market, Taiwan, Annual Cost of Therapy ($), 2017-2024
Figure 33: Atopic Dermatitis Therapeutics Market, Taiwan, Market Size ($m), 2017-2024
Figure 34: Atopic Dermatitis Therapeutics Market, Malaysia, Treatment Usage Patterns (million), 2017-2024
Figure 35: Atopic Dermatitis Therapeutics Market, Malaysia, Annual Cost of Therapy ($), 2017-2024
Figure 36: Atopic Dermatitis Therapeutics Market, Malaysia, Market Size ($m), 2017-2024
Figure 37: Atopic Dermatitis Therapeutics Market, Philippines, Treatment Usage Patterns (million), 2017-2024
Figure 38: Atopic Dermatitis Therapeutics Market, Philippines, Annual Cost of Therapy ($), 2017-2024
Figure 39: Atopic Dermatitis Therapeutics Market, Philippines, Market Size ($m), 2017-2024
Figure 40: Atopic Dermatitis Therapeutics Market, Thailand, Treatment Usage Patterns (million), 2017-2024
Figure 41: Atopic Dermatitis Therapeutics Market, Thailand, Annual Cost of Therapy ($), 2017-2024
Figure 42: Atopic Dermatitis Therapeutics Market, Thailand, Market Size ($m), 2017-2024
Figure 43: Atopic Dermatitis Therapeutics Market, Vietnam, Treatment Usage Patterns (million), 2017-2024
Figure 44: Atopic Dermatitis Therapeutics Market, Vietnam, Annual Cost of Therapy ($), 2017-2024
Figure 45: Atopic Dermatitis Therapeutics Market, Vietnam, Market Size ($m), 2017-2024
Figure 46: Atopic Dermatitis Therapeutics Market, Indonesia, Treatment Usage Patterns (million), 2017-2024
Figure 47: Atopic Dermatitis Therapeutics Market, Indonesia, Annual Cost of Therapy ($), 2017-2024
Figure 48: Atopic Dermatitis Therapeutics Market, Indonesia, Market Size ($m), 2017-2024
Figure 49:Atopic Dermatitis Therapeutics Market, Global, Licensing Deals by Region and Value, 2007-2018
Figure 50: Atopic Dermatitis Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2018
Figure 51: Atopic Dermatitis Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018
Figure 52: Atopic Dermatitis Therapeutics, Global, Licensing Deals by Molecule Type and Stage of Development, 2007-2018
Figure 53: Atopic Dermatitis Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007-2018
Figure 54:Atopic Dermatitis Therapeutics Market, Global, Co-development Deals by Region, 2007-2018 92

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amorepacific
  • Astellas
  • Cyclosporine
  • Eli Lilly and Incyte Corporation
  • Genentech
  • Kang Stem Biotech
  • LEO Pharma
  • Novartis
  • Pfizer
  • Regeneron
  • Sanofi
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll